Home・Список акций・Editas Medicine Inc

Editas Medicine Inc

Закрыт

СекторЗдравоохранение

2.87

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

2.81

Макс.

3.02

Ключевые показатели
By Trading Economics
Доход	6.8M -18M
Продажи	9.1M 12M
Прибыль на акцию	-0.15
Рентабельность продаж	-153.322
Сотрудники	87
EBITDA	3.9M -20M

Рекомендации
By TipRanks
Рекомендации	Покупка
Прогноз на 12 месяцев	+171.19% upside

Дивиденды
By Acuity
Следующий отчет о доходах	9 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	25M 432M
Предыдущая цена открытия	2.87
Предыдущая цена закрытия	2.87

Новостные настроения

By Acuity

63%

37%

279 / 340 Рейтинг в Healthcare

Editas Medicine Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

11 авг. 2026 г., 19:46 UTC

Editas Medicine Inc shares are trading higher today, reflecting unusual strength. No specific company news was identified to explain this price action.

10 авг. 2026 г., 23:26 UTC

Editas Medicine Inc shares are higher in after-market hours. No specific company news was identified to explain this movement amid broader market uncertainties.

7 авг. 2026 г., 23:16 UTC

Editas Medicine Inc. shares were little changed in after-market trading, with no specific news identified. The stock remains above its 20-day moving average.

6 авг. 2026 г., 23:02 UTC

Editas Medicine Inc shares are higher in after-market hours, reflecting positive momentum following a strong trading session despite no specific company news.

5 авг. 2026 г., 22:02 UTC

News

Editas Medicine reports second-quarter loss of $18.2 million, better than expected. Shares are higher after positive updates on EDIT-401 program and revenue growth.

31 июл. 2026 г., 19:56 UTC

Correlated Moves

EDIT shares lower amid broader biotech sector decline today.

30 июл. 2026 г., 23:51 UTC

Editas Medicine Inc shares are lower in after-market trading, continuing a decline since Thursday's close while remaining near the lower end of its one-month range.

29 июл. 2026 г., 23:46 UTC

Editas Medicine Inc shares are lower in after-market hours, with no specific news identified. The stock remains near its one-month low amid broader market caution.

28 июл. 2026 г., 20:07 UTC

Editas Medicine Inc shares are trading lower today, continuing a broader trend in the biotechnology sector. The stock remains below its 20-day moving average.

27 июл. 2026 г., 17:26 UTC

Editas Medicine Inc is trading higher today, following a notable peak. The upward movement comes amid easing inflation concerns from declining oil prices.

24 июл. 2026 г., 17:46 UTC

Editas Medicine Inc shares are lower today, continuing a trend of declines over the past three sessions amid broader market volatility linked to falling oil prices.

22 июл. 2026 г., 19:26 UTC

Editas Medicine Inc is lower today, continuing a decline since Tuesday's close. Broader market weakness may be influencing investor sentiment.

21 июл. 2026 г., 23:11 UTC

Editas Medicine Inc shares are higher in after-market hours, reflecting positive momentum since Tuesday's close, though they remain below their 20-day moving average.

Сравнение c конкурентами

Изменение цены

Editas Medicine Inc Прогноз

Целевая цена

By TipRanks

171.19% рост

Прогноз на 12 месяцев

Средняя 8 USD 171.19%

Максимум 15 USD

Минимум 4 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Editas Medicine Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

6 ratings

Покупка

Удержание

Продажа

Основано на мнении 6 аналитиков, присваивавших рейтинги акциям Editas Medicine Inc – Данные за последние 3 месяца.

Настроения

By Acuity

279 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.